What is the market doing?
What the tape says about AMLX
Amylyx Pharmaceuticals, Inc. is +373% over the past year while the S&P 500 is +23%: 350 points ahead of the market.
+373%
1-year return · S&P 500 +23%
- vs 200-day average
- +134%
vs 200-day average · a clear uptrend
- RSI (14)
- 76
RSI (14) · overbought, bought harder than it has been sold
- Below its 52-week high
- −6.6%
Below its 52-week high
Details›
- Last close2026-08-26
- $37.06
- 1 monthS&P 500 +3.7%
- +110%
- 1 yearS&P 500 +23%
- +373%
- vs 50-day average$20.56
- +80%
- 52-week high
- $39.67
- 52-week low
- $7.64
- Annualised volatility
- 79%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-06-30
- −$5.7M
| Year | Return |
|---|---|
| 2026 (year to date) | +207% |
| 2025 | +220% |
| 2024 | −74% |
| 2023 | −60% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 4 | 3 of 4 | +7.4% |
| Feb | 5 | 3 of 5 | +8.9% |
| Mar | 5 | 1 of 5 | −32% |
| Apr | 5 | 2 of 5 | −2.0% |
| May | 5 | 1 of 5 | −5.8% |
| Jun | 5 | 4 of 5 | +32% |
| Jul | 5 | 5 of 5 | +19% |
| Aug | 5 | 3 of 5 | +20% |
| Sep | 4 | 3 of 4 | +22% |
| Oct | 4 | 3 of 4 | +21% |
| Nov | 4 | 3 of 4 | +1.1% |
| Dec | 4 | 1 of 4 | −13% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers - Specialty & Generic
Ranks #3 of 28 by Smart Score